Literature DB >> 32100597

Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline 18F-FDG PET-CT.

Gauthier Delaby1, Marc-Antoine Hubaut1, Franck Morschhauser2, Alix Besson1, Damien Huglo1, Charles Herbaux2, Clio Baillet1.   

Abstract

We retrospectively investigated the prognostic value of the metabolic bulk volume (MBV), defined as the metabolic volume of the largest lesion, in 106 patients with diffuse large B-cell lymphoma who underwent baseline 18FDG PET-CT. Semi-automatically segmented (41% SUVmax) total metabolic tumor volume (TMTV) and MBV underwent receiver operating characteristic analysis, identifying optimal thresholds of 147 cm3 for the TMTV and 41.5 cm3 for the MBV. A low TMTV and a low MBV were significantly associated with longer progression-free survival (PFS) and overall survival (OS). According to Cox multivariate analysis, the TMTV and MBV were independent predictors, respectively, for PFS (HR = 3.501), and OS (HR = 7.242). The TMTV and MBV classification were discordant in 18.9% of patients with a 5-year PFS rate of 100% for patients with low MBV/high TMTV and 74% for high MBV/low TMTV. The baseline MBV can be an efficient tool for the risk stratification of aggressive lymphoma.

Entities:  

Keywords:  PET-CT; diffuse large B-cell lymphoma; metabolic bulk volume; total metabolic tumor volume

Mesh:

Substances:

Year:  2020        PMID: 32100597     DOI: 10.1080/10428194.2020.1728750

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.

Authors:  Lale Kostakoglu; Federico Mattiello; Maurizio Martelli; Laurie H Sehn; David Belada; Chiara Ghiggi; Neil Chua; Eva González-Barca; Xiaonan Hong; Antonio Pinto; Yuankai Shi; Yoichi Tatsumi; Christopher Bolen; Andrea Knapp; Gila Sellam; Tina Nielsen; Deniz Sahin; Umberto Vitolo; Marek Trněný
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

2.  The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.

Authors:  Joon Ho Choi; Ilhan Lim; Byung Hyun Byun; Byung Il Kim; Chang Woon Choi; Hye Jin Kang; Dong-Yeop Shin; Sang Moo Lim
Journal:  PLoS One       Date:  2022-09-26       Impact factor: 3.752

3.  Bilateral renal involvement in diffuse large B-cell lymphoma on fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Yassir Benameur; Adnane Hammani; Kamal Doghmi; Abderrahim Doudouh
Journal:  World J Nucl Med       Date:  2021-02-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.